Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
Tikkanen MJ, Holme I, Cater NB, Szarek M, Faergeman O, Kastelein JJ, Olsson AG, Larsen ML, Lindahl C, Pedersen TR; Incremental DEcrease through Aggressive Lipid Lowering Investigators. Tikkanen MJ, et al. Among authors: olsson ag. Am J Cardiol. 2009 Mar 1;103(5):577-82. doi: 10.1016/j.amjcard.2008.10.029. Epub 2009 Jan 17. Am J Cardiol. 2009. PMID: 19231315 Clinical Trial.
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S).
Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyörälä K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ. Pedersen TR, et al. Among authors: olsson ag. Circulation. 1998 Apr 21;97(15):1453-60. doi: 10.1161/01.cir.97.15.1453. Circulation. 1998. PMID: 9576425 Clinical Trial.
Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering.
Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, Kristianson J, Berg K, Cook TJ, Haghfelt T, Kjekshus J, Miettinen T, Olsson AG, Pyörälä K, Wedel H. Pedersen TR, et al. Among authors: olsson ag. Am J Cardiol. 2000 Aug 1;86(3):257-62. doi: 10.1016/s0002-9149(00)00910-3. Am J Cardiol. 2000. PMID: 10922429 Clinical Trial.
Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction.
Strandberg TE, Holme I, Faergeman O, Kastelein JJ, Lindahl C, Larsen ML, Olsson AG, Pedersen TR, Tikkanen MJ; IDEAL Study Group. Strandberg TE, et al. Among authors: olsson ag. Am J Cardiol. 2009 May 15;103(10):1381-5. doi: 10.1016/j.amjcard.2009.01.377. Epub 2009 Mar 25. Am J Cardiol. 2009. PMID: 19427432 Clinical Trial.
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial.
Tikkanen MJ, Szarek M, Fayyad R, Holme I, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Larsen ML, Lindahl C, Pedersen TR; IDEAL Investigators. Tikkanen MJ, et al. Among authors: olsson ag. J Am Coll Cardiol. 2009 Dec 15;54(25):2353-7. doi: 10.1016/j.jacc.2009.08.035. J Am Coll Cardiol. 2009. PMID: 20082922 Free article. Clinical Trial.
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels.
Tikkanen MJ, Fayyad R, Faergeman O, Olsson AG, Wun CC, Laskey R, Kastelein JJ, Holme I, Pedersen TR; IDEAL Investigators. Tikkanen MJ, et al. Among authors: olsson ag. Int J Cardiol. 2013 Oct 9;168(4):3846-52. doi: 10.1016/j.ijcard.2013.06.024. Epub 2013 Aug 31. Int J Cardiol. 2013. PMID: 24001698 Clinical Trial.
315 results